Physician profile
Lawrence E Banta
NPI 1568440295
$2,810.66
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $271 · 2021: $513 · 2022: $765 · 2023: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $457 · Education: $67.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.02 |
| Education | $67.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $421.14 | 2019-2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $254.00 | 2019-2023 | Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $236.29 | 2019-2023 | Austedo |
| Janssen Pharmaceuticals, INC | $234.17 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $223.93 | 2020-2023 | |
| Sunovion Pharmaceuticals INC. | $220.00 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $201.24 | 2021-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $124.09 | 2019-2023 | Trintellix |
| Lundbeck LLC | $97.71 | 2020-2023 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $86.22 | 2019-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $82.72 | 2019-2023 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $73.57 | 2019-2023 | Jornay Pm |
| Allergan, INC. | $73.30 | 2019-2020 | |
| Abbvie INC. | $68.15 | 2022-2023 | Vraylar |
| Jazz Pharmaceuticals INC. | $67.00 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $66.58 | 2021-2023 | Ingrezza |
| Eisai INC. | $63.73 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $63.21 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $42.83 | 2019-2022 | |
| Indivior INC. | $31.39 | 2022 | |
| Corium, LLC | $23.72 | 2022-2023 | Azstarys |
| Tris Pharma INC | $20.44 | 2023 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $18.97 | 2023 | Auvelity |
| Idorsia Pharmaceuticals US INC | $16.26 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Banta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.